{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:13:31Z","timestamp":1793686411744,"version":"4.5.1"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population. Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6 receptor, has emerged as an effective treatment for RA. This narrative review provides an update on TCZ\u2019s efficacy and safety based on data from randomized controlled trials (RCTs) and real-world evidence (RWE). TCZ, available in subcutaneous (SC) and intravenous (IV) formulations, has shown significant benefits in RA management. Key clinical trials, including SAMURAI, OPTION, RADIATE, and TOWARD, have demonstrated TCZ\u2019s efficacy as monotherapy and in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), particularly in patients with inadequate responses to methotrexate or TNF inhibitors. Long-term studies, such as STREAM, have highlighted TCZ\u2019s sustained efficacy and favorable safety profile over 5 years. The impact of TCZ on cardiovascular health, lipid profiles, and the risk of infections has been a focal point, with findings suggesting no significant increase in cardiovascular disease risk compared to other RA therapies. RWE further highlights the effectiveness of TCZ, identifying predictors of response, such as age, and emphasizes its suitability for biologic-na\u00efve and overweight patients. Special considerations include TCZ use in RA-associated interstitial lung disease and amyloidosis. Overall, TCZ remains a pivotal option in RA treatment, with a well-established safety and efficacy profile supported by extensive clinical and real-world data.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1470488","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:32:48Z","timestamp":1740360768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Update on tocilizumab in rheumatoid arthritis: a narrative review"],"prefix":"10.3389","volume":"16","author":[{"given":"Simone","family":"Parisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Ditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ghellere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Panaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Piccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes131","article-title":"Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study","volume":"51","author":"Strand","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062148","article-title":"Clinical features of diabetes mellitus on rheumatoid arthritis: data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) study group","volume":"12","author":"Cacciapaglia","year":"2023","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155238","article-title":"Interleukin-6 in rheumatoid arthritis","volume":"21","author":"Pandolfi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"Deane","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14194","article-title":"A bond between rheumatic diseases and cancer in the elderly: the interleukin-6 pathway","volume":"24","author":"Iorio","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40259-023-00634-1","article-title":"Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned","volume":"38","author":"Avci","year":"2024","journal-title":"BioDrugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4155\/CLI.10.28","article-title":"Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program","volume":"1","author":"Rueda","year":"2011","journal-title":"Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"R4RA collaborative group. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/annrheumdis-2021-221366","article-title":"2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19","volume":"81","author":"Alunno","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B19","unstructured":"Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Actemra"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255533","article-title":"Interleukin 6: at the interface of human health and disease","volume":"14","author":"Grebenciucova","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/BTT.S101289","article-title":"Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years","volume":"10","author":"Farah","year":"2016","journal-title":"Biologics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1795","article-title":"Differential binding of sarilumab and tocilizumab to IL-6R\u03b1 and effects of receptor occupancy on clinical parameters","volume":"61","author":"Xu","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215266","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19","volume":"76","author":"Khan","year":"2021","journal-title":"Thorax"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/k0ctlf","article-title":"Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients","volume":"41","author":"Saito","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B25","unstructured":"Study VI (WA19926)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0266462318003628","article-title":"Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis","volume":"35","author":"Simpson","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22110","article-title":"Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis","volume":"66","author":"Ogata","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","article-title":"A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex391","article-title":"Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis","volume":"57","author":"Choy","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1254753","article-title":"Dyslipidemia in rheumatoid arthritis: the possible mechanisms","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.trsl.2016.12.003","article-title":"Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation","volume":"183","author":"Ruiz-Lim\u00f3n","year":"2017","journal-title":"Transl Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110340","article-title":"Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial","volume":"38","author":"Kume","year":"2011","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","article-title":"Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice","volume":"53","author":"Pers","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.15406\/mojor.2017.08.00317","article-title":"Efficacy and rapid response of tocilizumab in rheumatoid arthritis patients not responder to previous biologic therapy","volume":"8","author":"Parisi","year":"2017","journal-title":"MOJ Orthop Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213416","article-title":"Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B44","article-title":"A study of the efficacy and safety of subcutaneous injections of tocilizumab in adults with rheumatoid arthritis","volume":"22","author":"Langevitz","year":"2020","journal-title":"Isr Med Assoc J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-020-02233-9","article-title":"Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry","volume":"22","author":"Kawabe","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac038","article-title":"Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study","volume":"6","author":"Nagy","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371542","article-title":"Rheumatoid arthritis and lung disease: from mechanisms to a practical approach","volume":"35","author":"Lake","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6982","article-title":"Organizing pneumonia induced by tocilizumab in a patient with rheumatoid arthritis","volume":"12","author":"Gouveia","year":"2020","journal-title":"Cureus"},{"key":"B49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1753465816668780","article-title":"Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review","volume":"11","author":"Picchianti Diamanti","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0190-z","article-title":"Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced","volume":"74","author":"Hallowell","year":"2014","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003353","article-title":"Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning","volume":"10","author":"Rom\u00e1n Ivorra","year":"2024","journal-title":"RMD Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"B55","article-title":"Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments","volume":"29","author":"Nakamura","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B56","article-title":"Successful treatment of rheumatoid arthritis-associated renal AA amyloidosis with tocilizumab","volume":"22","author":"Kov\u00e1cs","year":"2020","journal-title":"Isr Med Assoc J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.5551\/jat.62764","article-title":"Effectiveness and safety of lipid-lowering drug treatments in Japanese patients with familial hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study","volume":"29","author":"Yamashita","year":"2022","journal-title":"J Atheroscler Thromb"},{"key":"B58","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5414\/CN109971","article-title":"Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: two case reports","volume":"95","author":"Fukuda","year":"2021","journal-title":"Clin Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1099-18","article-title":"First nationwide survey of 199 patients with amyloid A amyloidosis in Japan","volume":"57","author":"Okuda","year":"2018","journal-title":"Intern Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2879-0","article-title":"Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice","volume":"34","author":"Backhaus","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/13506129.2014.1002031","article-title":"AA amyloidosis treated with tocilizumab: case series and updated literature review","volume":"22","author":"Courties","year":"2015","journal-title":"Amyloid"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez535","article-title":"Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis","volume":"59","author":"Sch\u00e4fer","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis: a systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2627","article-title":"The cellular and signaling networks linking the immune system and metabolism in disease","volume":"18","author":"Osborn","year":"2012","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/art.30158","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2641-y","article-title":"Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes","volume":"55","author":"Schipper","year":"2012","journal-title":"Diabetologia"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8886-21","article-title":"Adult-onset Still\u2019s disease during pregnancy treated with tocilizumab","volume":"61","author":"Imaizumi","year":"2022","journal-title":"Intern Med"},{"key":"B68","article-title":"Tocilizumab throughout pregnancy in two patients with severe Takayasu\u2019s arteritis","volume":"46","author":"Cruz-MaChado","year":"2021","journal-title":"Acta Reumatol Port"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez100","article-title":"Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum","volume":"58","author":"Saito","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1711","article-title":"POS0615: Tocilizumab is safe and effective in elderly patients with rheumatoid arthritis","volume":"80","author":"Specker","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/f7ff6q","article-title":"The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age","volume":"40","author":"Specker","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1177\/20587392211045790","article-title":"Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: a real-world observational study","volume":"19","author":"Nakao","year":"2021","journal-title":"Eur J Inflammation"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-00178-w","article-title":"Accelerated immunosenescence in rheumatoid arthritis: impact on clinical progression","volume":"17","author":"Bauer","year":"2020","journal-title":"Immun Ageing"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120447","article-title":"Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results","volume":"40","author":"Fleischmann","year":"2013","journal-title":"J Rheumatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"gnant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1827-x","article-title":"Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review","volume":"30","author":"Gout","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8031-21","article-title":"A rare case of rheumatoid arthritis with tocilizumab-induced intestinal mucosal injury","volume":"61","author":"Ohkubo","year":"2022","journal-title":"Intern Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab438","article-title":"Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept","volume":"61","author":"Rempenault","year":"2022","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1470488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:32:52Z","timestamp":1740360772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1470488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":81,"alternative-id":["10.3389\/fimmu.2025.1470488"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1470488","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"article-number":"1470488"}}